RE:RE:The Big Picture - forecasting the futureWe are all in the same boat. Holding VMD during the pandemic was not unreasonable given that business was only on pause due to hospital access for new patients. Twice when the covid abated the company reported a return to higher uploads of new patients. But Covid kept returning with new variants. Fortunately Omicron looks like it will end the pandemic.
In their most recent Q3, Todd Zehnder stated:
October was a good reversal; although it wasn't as strong as July, it was better than September, so we look at trends a lot of times, and we look at cities and how many of our reps are having struggles versus not having access struggles, if you will, and the fact that October had a positive trend from new patients is a good sign, although still hoping to get back to that full access that we saw in July that, like Casey said, was probably our best month in the last year-and-a-half since the pandemic started.
And then there is Casey Hoyt's comment at Stifel in November where he expect core business for the year to be in the high teens.
All the changes during the pandemic to the company and environment listed at the beginning of the Big Picture thread (Working capital, virtual platforms, software investment, hospital reputation, home health acceptance, research on NIV for COPD, reimbursement rates, OIG, management resilience, hiring) suggests to me that VieMed is in the right place at the right time at the end of the pandemic.